Represents the initial period of the collaborative agreement.

No definition available.

Name:	imgn_CollaborativeArrangementAgreementTerm
Namespace Prefix:	imgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The Company?s development and commercialization license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration, or FDA, or other countries? regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementMilestonePaymentsPotential
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The number of hematology-related antibody-drug conjugate (ADC) programs under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementNumberOfAntiBodyDrugConjugatePrograms
Namespace Prefix:	imgn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of early stage hematology-related antibody-drug conjugate (ADC) programs under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementNumberOfEarlyStageAntiBodyDrugConjugatePrograms
Namespace Prefix:	imgn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of product for which there is right to co-commercialize in the U.S. under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementNumberOfProductRightToCoCommercialize
Namespace Prefix:	imgn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of reimbursement received under collaborative arrangement.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementReimbursementReceived
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the number of single-target licenses the company has right to use.

+ References

No definition available.

+ Details

Name:	imgn_NumberOfSingleTargetLicenses
Namespace Prefix:	imgn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=imgn_JazzPharmaceuticalsIrelandLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Agreements - Jazz Pharmaceuticals (Details) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
Agreements - Jazz Pharmaceuticals (Details) $ in Thousands	Aug. 31, 2017 USD ($) product item	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)
Collaborative Agreements disclosures
Remaining arrangement consideration to be recognized as license revenue		$ 80,592		$ 80,592		$ 93,752
Jazz Pharmaceuticals
Collaborative Agreements disclosures
Number of early stage ADC programs \| item	2
Number of ADC programs \| item	3
Payments received under collaboration agreement	$ 75,000
Term of agreement	7 years
Number of products with rights to co-commercialize \| product	1
Offset to research and development expense		3,300	$ 1,300	7,100	$ 1,300
Number of development and commercialization licenses \| item	3
Remaining arrangement consideration to be recognized as license revenue	$ 75,000	$ 75,000		$ 75,000
Jazz Pharmaceuticals \| Maximum
Collaborative Agreements disclosures
Potential milestone payment	$ 100,000